8-K filed March 3, 2026, 6:59 PM ET ticker TSEOF CIK 0001519061

regulatory confidence high sentiment negative materiality 1.00

NYSE commences delisting proceedings for Trinseo after market cap falls below $15M

Trinseo PLC

Received NYSE notice on March 2, 2026; trading suspended immediately due to average market cap < $15M over 30 days.
Previously disclosed non-compliance: average market cap below $50M and share price below $1.00 in December 2025.
Delisting effective 10 days after NYSE files Form 25; shares may trade on OTC Pink, but no assurance.
Irish stamp duty of 1% applies on trades; DTC will cease clearing trades, requiring direct registration with transfer agent.
Company states delisting does not affect business operations, relationships, or SEC reporting obligations.

item 3.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001104659-26-022537
form_type: 8-K
ticker: TSEOF
cik: 0001519061
company_name: Trinseo PLC
filed_at: 2026-03-03T23:59:59+00:00
discovered_at: 2026-05-14T18:02:35.301133+00:00
generated_at: 2026-05-15T22:14:28.005232+00:00
sec_items: ["3.01", "9.01"]
event_type: regulatory
sentiment: negative
materiality_score: 1.0
calibrated_materiality_score: 1.0
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001104659-26-022537
json_url: https://secwatch.observer/filing/0001104659-26-022537.json
markdown_url: https://secwatch.observer/filing/0001104659-26-022537.md
text_url: https://secwatch.observer/filing/0001104659-26-022537.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1519061/000110465926022537/0001104659-26-022537-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1519061/000110465926022537/tse-20260302x8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source-grounded claims

0a794b87e8b029fed8d2edb640f9f77e9f6a1382

Trinseo PLC received a nyse delisting notice notice regarding other (rules 802.01B).

“Company”) received written notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) that the NYSE had determined to commence proceedings to delist the Company’s ordinary shares. As stated in the Notice, the NYSE reached its decision to delist the Company’s securities pursuant to Section 802.01B of the NYSE Listed Company Manual because the Company had fallen below the NYSE continued listing standard requiring listed companies to maintain an average market capitalization over a 30-trading day period of at least $15 million. The Notice also stated that trading in the Company’s ordina

SEC 8-K Item 3.01 confidence 0.9 SEC evidence

8b3507d1cb80a264cc3678641d4ddb0ae9d5237c

Trinseo PLC received a nyse delisting notice notice regarding minimum bid price (rules 802.01C).

ive 30 trading-day period was less than $50 million and, at the same time, its stockholders’ equity was less than $50 million. In addition, the Company also received written notice from the NYSE indicating that it was not in compliance with the NYSE’s continued listing standard set forth in Section 802.01C because its average closing share price had fallen below $1.00 per share for 30 consecutive trading days. As stated in the Notice, the NYSE will file a Form 25 with the SEC to delist the Company’s ordinary shares from the NYSE upon completion of applicable procedures. The delisting will be

SEC 8-K Item 3.01 confidence 0.9 SEC evidence

Comparable filings

SONM

DNA X receives Nasdaq delisting notice; issues $3.05M convertible note to insider

DNA X, Inc. May 27, 2026, 4:35 PM ET regulatory Items 1.01, 2.03, 3.01, 3.02, 9.01

same fact type: exchange_compliance_notice same SEC item: 3.01, 9.01 same event type: regulatory similar materiality

This filing

“Company”) received written notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) that the NYSE had determined to commence proceedings to delist the Company’s ordinary shares. As stated in the Notice, the NYSE reached its decision to delist the Company’s securities pursuant to Section 802.01B of the NYSE Listed Company Manual because the Company had fallen below the NYSE continued listing standard requiring listed companies to maintain an average market capitalization over a 30-trading day period of at least $15 million. The Notice also stated that trading in the Company’s ordina

Comparable filing

May 22, 2026, the Company received a delisting determination letter from the Staff advising the Company that unless the Company requests a hearing before a Nasdaq Hearing Panel (the “Panel”) to appeal Nasdaq’s delisting

Filing page SEC filing

ADTX

Aditxt receives Nasdaq delisting notice for bid price non-compliance; to appeal

Aditxt, Inc. May 8, 2026, 7:59 PM ET regulatory Items 3.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 3.01, 9.01 same event type: regulatory similar materiality

This filing

“Company”) received written notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) that the NYSE had determined to commence proceedings to delist the Company’s ordinary shares. As stated in the Notice, the NYSE reached its decision to delist the Company’s securities pursuant to Section 802.01B of the NYSE Listed Company Manual because the Company had fallen below the NYSE continued listing standard requiring listed companies to maintain an average market capitalization over a 30-trading day period of at least $15 million. The Notice also stated that trading in the Company’s ordina

Comparable filing

May 6, 2026, Aditxt, Inc. (the “Company”) received a Staff Determination letter (the “Staff Determination”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that

Filing page SEC filing

TPST

Tempest Therapeutics warned by Nasdaq for low equity and board independence; two directors resign

Tempest Therapeutics, Inc. May 22, 2026, 5:28 PM ET regulatory Items 3.01, 5.02

same fact type: exchange_compliance_notice same SEC item: 3.01 same event type: regulatory similar materiality

This filing

“Company”) received written notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) that the NYSE had determined to commence proceedings to delist the Company’s ordinary shares. As stated in the Notice, the NYSE reached its decision to delist the Company’s securities pursuant to Section 802.01B of the NYSE Listed Company Manual because the Company had fallen below the NYSE continued listing standard requiring listed companies to maintain an average market capitalization over a 30-trading day period of at least $15 million. The Notice also stated that trading in the Company’s ordina

Comparable filing

May 22, 2026, Tempest Therapeutics, Inc. (the “Company”) notified the Nasdaq Stock Market LLC (“Nasdaq”) that the Company will not be in compliance with the majority independent director requirement under Nasdaq Listing

Filing page SEC filing

TOMZ

TOMI Environmental receives Nasdaq delisting notice for bid price, equity non-compliance

TOMI Environmental Solutions, Inc. May 20, 2026, 9:00 AM ET regulatory Items 3.01

same fact type: exchange_compliance_notice same SEC item: 3.01 same event type: regulatory similar materiality

This filing

“Company”) received written notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) that the NYSE had determined to commence proceedings to delist the Company’s ordinary shares. As stated in the Notice, the NYSE reached its decision to delist the Company’s securities pursuant to Section 802.01B of the NYSE Listed Company Manual because the Company had fallen below the NYSE continued listing standard requiring listed companies to maintain an average market capitalization over a 30-trading day period of at least $15 million. The Notice also stated that trading in the Company’s ordina

Comparable filing

May 19, 2026, the Company received a letter (the “Letter”) from the Listing Qualifications Department (the “Staff”) of Nasdaq notifying the Company that because it failed to regain compliance with each of the Bid Price R

Filing page SEC filing

PRPL

Purple Innovation receives Nasdaq delisting determination; will appeal by May 12

Purple Innovation, Inc. May 11, 2026, 4:15 PM ET regulatory Items 3.01

same fact type: exchange_compliance_notice same SEC item: 3.01 same event type: regulatory similar materiality

This filing

“Company”) received written notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) that the NYSE had determined to commence proceedings to delist the Company’s ordinary shares. As stated in the Notice, the NYSE reached its decision to delist the Company’s securities pursuant to Section 802.01B of the NYSE Listed Company Manual because the Company had fallen below the NYSE continued listing standard requiring listed companies to maintain an average market capitalization over a 30-trading day period of at least $15 million. The Notice also stated that trading in the Company’s ordina

Comparable filing

May 5, 2026, Purple Innovation, Inc. (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as notified by Nasdaq on November 5, 2025, the bid price of the Company’s Class A common stock had closed at less than $1.00 per share over the previous 30 consecutive business days, and, as a result, did not comply with Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”). In accordance with Listing Rule 5810(c)(3)(A), the Company was provided 180 calendar days, or until May 4, 2026, to regain compliance with the

Filing page SEC filing

GENC

Gencor receives NYSE American delinquency notice for late Q2 2026 10-Q filing

GENCOR INDUSTRIES INC June 1, 2026, 4:09 PM ET regulatory Items 3.01, 7.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 3.01, 9.01 same event type: regulatory

This filing

“Company”) received written notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) that the NYSE had determined to commence proceedings to delist the Company’s ordinary shares. As stated in the Notice, the NYSE reached its decision to delist the Company’s securities pursuant to Section 802.01B of the NYSE Listed Company Manual because the Company had fallen below the NYSE continued listing standard requiring listed companies to maintain an average market capitalization over a 30-trading day period of at least $15 million. The Notice also stated that trading in the Company’s ordina

Comparable filing

May 19, 2026, Gencor Industries, Inc. (the “Company”) received a notice (the “Delinquency Notification”) from NYSE Regulation (the “NYSE”) indicating the Company was not in compliance with the NYSE American LLC (“NYSE American”) continued listing standards as a result of its failure to timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2026 (the “Form 10-Q”) with the Securities and Exchange Commission (“SEC”) prior to May 18, 2026, the end of the extension period provided by Form 12b-25, and as a result was subject to the procedures set forth in Section 1007 of the NY

Filing page SEC filing

ATNM

Actinium receives NYSE American non-compliance notice for low stockholders' equity; must submit plan by June 26

Actinium Pharmaceuticals, Inc. May 29, 2026, 5:10 PM ET regulatory Items 3.01, 7.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 3.01, 9.01 same event type: regulatory

This filing

“Company”) received written notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) that the NYSE had determined to commence proceedings to delist the Company’s ordinary shares. As stated in the Notice, the NYSE reached its decision to delist the Company’s securities pursuant to Section 802.01B of the NYSE Listed Company Manual because the Company had fallen below the NYSE continued listing standard requiring listed companies to maintain an average market capitalization over a 30-trading day period of at least $15 million. The Notice also stated that trading in the Company’s ordina

Comparable filing

May 27, 2026, Actinium Pharmaceuticals, Inc. (the “Company”) received a notice (the “Notice”) from NYSE American LLC (“NYSE American”) indicating that the Company is not in compliance with the continued listing standards set forth in Section 1003(a)(ii) of the NYSE American Company Guide (the “Company Guide”), which requires a listed company to maintain stockholders’ equity of $4.0 million or more if it has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. As of March 31, 2026, the Company reported stockholders’ equity of approximately

Filing page SEC filing

CSAI

Cloudastructure receives Nasdaq delinquency notice for late Q1 10-Q filing

CLOUDASTRUCTURE, INC. May 29, 2026, 5:09 PM ET regulatory Items 3.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 3.01, 9.01 same event type: regulatory

This filing

“Company”) received written notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) that the NYSE had determined to commence proceedings to delist the Company’s ordinary shares. As stated in the Notice, the NYSE reached its decision to delist the Company’s securities pursuant to Section 802.01B of the NYSE Listed Company Manual because the Company had fallen below the NYSE continued listing standard requiring listed companies to maintain an average market capitalization over a 30-trading day period of at least $15 million. The Notice also stated that trading in the Company’s ordina

Comparable filing

May 26, 2026, Cloudastructure, Inc. (the “Company”) received a notice (the “Notice”) from the Nasdaq Listing Qualifications staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of not having timely filed its Quarterly Report on Form 10-Q for the period ended March 31, 2026 (“Form 10-Q”), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of all required periodic financial reports with the Securities and Exchange Commission. The Company requires additional time to review and confirm the accounting treatment for its outstand

Filing page SEC filing

Source: SEC EDGAR

accession 0001104659-26-022537

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.